Clinical Trials

Carcinoma, Hepatocellular

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

55 enrolled

Carcinoma, Hepatocellular

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

433 enrolled 26 charts

Carcinoma, Hepatocellular

NCT03937830 2026-02-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

27 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06040099 2026-01-20

EMERALD-Y90

56 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

32 enrolled

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT07081633 2025-12-30

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT06880523 2025-12-18

SLIDE-HCC

140 enrolled

Carcinoma, Hepatocellular

NCT05733598 2025-12-15

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

60 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

21 enrolled

Carcinoma, Hepatocellular

NCT06994299 2025-11-18

PRISM

Phase 2 Withdrawn

Carcinoma, Hepatocellular

NCT06698250 2025-11-06

ZENOBIA

40 enrolled

Carcinoma, Hepatocellular

NCT06999694 2025-09-10

Proton-STRIDE

45 enrolled

Carcinoma, Hepatocellular

NCT05194293 2025-09-04

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

4 enrolled

Carcinoma, Hepatocellular

NCT03638141 2025-08-17

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Phase 2 Completed

21 enrolled 12 charts

Phase 2 Not yet recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07122089 2025-08-14

IOSPHERE

80 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular

NCT07012798 2025-06-10

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT06999707 2025-06-05

Photon-STRIDE

45 enrolled

Carcinoma, Hepatocellular

NCT06045975 2025-04-02

DUMELEP

Carcinoma, Hepatocellular

NCT03899428 2025-03-24

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Carcinoma, Hepatocellular

NCT05027425 2024-11-22

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

NCT05844046 2024-07-16

MONTBLANC

83 enrolled

Carcinoma, Hepatocellular

NCT04988945 2023-09-06

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

33 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05809869 2023-04-12

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

25 enrolled

Carcinoma, Hepatocellular

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05312216 2023-01-26

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

25 enrolled

Carcinoma, Hepatocellular

NCT03482102 2022-09-08

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

70 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT04961918 2021-07-14

The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)

36 enrolled

Carcinoma, Hepatocellular

NCT04913480 2021-06-04

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

37 enrolled